Portal de Periódicos da CAPES

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels

2007; Springer Nature; Volume: 96; Issue: 3 Linguagem: Inglês

10.1038/sj.bjc.6603596

1532-1827

Keiran S.M. Smalley, Rooha Contractor, Nikolas K. Haass, J T Lee, Katherine L. Nathanson, Calvo Medina, Keith T. Flaherty, Meenhard Herlyn,

Cellular Mechanics and Interactions

The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.